Nishigaki A, Noma H, Kakizawa T
Shikwa Gakuho. 1989 Mar;89(3):639-62.
Tail-vein injections of streptozotocin (STZ) in various doses (20-60 mg/kg body weight) were used to induce diabetes mellitus in male rats of the Sprague-Dawley strain. Resulting pathosis was observed on the basis of various parameters (body weight, blood glucose, plasma insulin, glucose-tolerance tests, uroscopy, hemodiagnosis, and skin strength) Results 1. Diabetes mellitus was induced in all rats of the group in which the dosage was STZ 40 mg/kg body weight (S-40 group). Blood-glucose level in this group was about 340 mg (3 times the quantity in controls). Plasma-insulin level was about 8.9 microU/ml (about 1/3 the quantity in controls). Glucose-tolerance tests and observation of urino-glucose showed reductions in glucose tolerance and plasma-insulin response. 2. In the S-40 group, pathosis of induced diabetes mellitus had stabilized 30 days after and persisted for 90 days after STZ injection. 3. Skin strength decreased for 20 days after STZ injection. The level remained stable at half the strength of control skin from 30 to 90 days after the injection. 4. In groups in which doses were STZ 20 mg/kg body weight or STZ 30 mg/kg body weight, diabetes mellitus was induced in some of the rats. The animals tended to recover from the induced pathosis. 5. Diabetes mellitus was induced in all rats to which doses of STZ 50 mg/kg or STZ60 mg/kg body weight were induced. shortly after injection, the induced-diabetes pathosis changed for the worse; and grave complications (hypo-albuminosis, diabetic ketocacidosis, and diabetic proteinuria) were observed. A large number of the rats in these groups died. 6. The results of this study confirm the opinion that STZ 40 mg/kg body weight is the optimum dose for STZ induction of diabetes mellitus in rats for experimental studies. The suitable term for such studies is from 30 to 90 days after STZ injection.
采用不同剂量(20 - 60毫克/千克体重)的链脲佐菌素(STZ)经尾静脉注射,诱导斯普拉格 - 道利品系雄性大鼠患糖尿病。根据各种参数(体重、血糖、血浆胰岛素、葡萄糖耐量试验、尿液检查、血液诊断和皮肤强度)观察所产生的病变。结果:1. 在剂量为STZ 40毫克/千克体重的组中,所有大鼠均诱发糖尿病(S - 40组)。该组血糖水平约为340毫克(是对照组的3倍)。血浆胰岛素水平约为8.9微单位/毫升(约为对照组的1/3)。葡萄糖耐量试验和尿糖观察显示葡萄糖耐量和血浆胰岛素反应降低。2. 在S - 40组中,诱导糖尿病的病变在STZ注射后30天稳定,并在注射后持续90天。3. STZ注射后皮肤强度下降20天。注射后30至90天,该水平保持稳定,为对照皮肤强度的一半。4. 在剂量为STZ 20毫克/千克体重或STZ 30毫克/千克体重的组中,部分大鼠诱发糖尿病。动物倾向于从诱发的病变中恢复。5. 在所有注射剂量为STZ 50毫克/千克或STZ 60毫克/千克体重的大鼠中均诱发糖尿病。注射后不久,诱发的糖尿病病变恶化;并观察到严重并发症(低白蛋白血症、糖尿病酮症酸中毒和糖尿病蛋白尿)。这些组中的大量大鼠死亡。6. 本研究结果证实了以下观点:STZ 40毫克/千克体重是用于实验研究中STZ诱导大鼠糖尿病的最佳剂量。此类研究的合适期限是在STZ注射后30至90天。